Silvercrest Asset Management Group LLC Reduces Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Silvercrest Asset Management Group LLC lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 10.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,991 shares of the medical equipment provider's stock after selling 6,137 shares during the quarter. Silvercrest Asset Management Group LLC's holdings in Intuitive Surgical were worth $27,659,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Essex Savings Bank increased its position in shares of Intuitive Surgical by 22.9% during the fourth quarter. Essex Savings Bank now owns 660 shares of the medical equipment provider's stock valued at $344,000 after acquiring an additional 123 shares during the last quarter. Outlook Wealth Advisors LLC increased its position in shares of Intuitive Surgical by 7.1% during the fourth quarter. Outlook Wealth Advisors LLC now owns 437 shares of the medical equipment provider's stock valued at $228,000 after acquiring an additional 29 shares during the last quarter. Carnegie Investment Counsel increased its position in shares of Intuitive Surgical by 33.3% during the fourth quarter. Carnegie Investment Counsel now owns 653 shares of the medical equipment provider's stock valued at $341,000 after acquiring an additional 163 shares during the last quarter. Ritholtz Wealth Management increased its position in shares of Intuitive Surgical by 1.0% during the fourth quarter. Ritholtz Wealth Management now owns 4,465 shares of the medical equipment provider's stock valued at $2,331,000 after acquiring an additional 44 shares during the last quarter. Finally, JGP Wealth Management LLC increased its position in shares of Intuitive Surgical by 2.1% during the fourth quarter. JGP Wealth Management LLC now owns 2,095 shares of the medical equipment provider's stock valued at $1,094,000 after acquiring an additional 44 shares during the last quarter. Institutional investors own 83.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wells Fargo & Company increased their price target on Intuitive Surgical from $630.00 to $687.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. CICC Research began coverage on Intuitive Surgical in a report on Monday, January 27th. They issued a "neutral" rating and a $550.00 price objective for the company. Raymond James upped their price objective on shares of Intuitive Surgical from $560.00 to $688.00 and gave the company an "outperform" rating in a report on Friday, January 24th. Citigroup lifted their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a "buy" rating in a research note on Friday, January 24th. Finally, Jefferies Financial Group upped their price target on shares of Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $598.95.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded down $4.47 during mid-day trading on Tuesday, reaching $557.16. 1,233,924 shares of the company's stock traded hands, compared to its average volume of 1,644,792. Intuitive Surgical, Inc. has a 12-month low of $396.15 and a 12-month high of $616.00. The firm has a market capitalization of $199.70 billion, a price-to-earnings ratio of 86.92, a PEG ratio of 5.85 and a beta of 1.70. The company has a 50 day moving average price of $506.50 and a 200-day moving average price of $537.23.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The firm had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter in the prior year, the business earned $1.50 EPS. As a group, analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Robert Desantis sold 11,545 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $499.22, for a total value of $5,763,494.90. Following the completion of the sale, the executive vice president now directly owns 5,224 shares in the company, valued at $2,607,925.28. This represents a 68.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Myriam Curet sold 2,401 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $581.00, for a total value of $1,394,981.00. Following the completion of the transaction, the executive vice president now directly owns 353 shares in the company, valued at approximately $205,093. This represents a 87.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,700 shares of company stock worth $16,865,621 in the last three months. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.